Pulmonary venoocclusive disease

From WikiMD's WELLNESSPEDIA

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Pulmonary veno-occlusive disease
Synonyms PVOD
Pronounce N/A
Specialty N/A
Symptoms Shortness of breath, fatigue, cough, hemoptysis
Complications Pulmonary hypertension, right heart failure
Onset Typically in adulthood
Duration Chronic
Types N/A
Causes Often idiopathic, can be associated with connective tissue disease, HIV/AIDS, certain drugs
Risks Genetic predisposition, environmental factors
Diagnosis High-resolution computed tomography, lung biopsy
Differential diagnosis Pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension
Prevention N/A
Treatment Lung transplantation, supportive care
Medication Diuretics, oxygen therapy
Prognosis Poor without lung transplantation
Frequency Rare
Deaths N/A


Pulmonary venoocclusive disease (PVOD) is a rare form of pulmonary hypertension characterized by the obstruction of the small pulmonary veins in the lungs. This condition leads to increased pressure in the pulmonary circulation, which can result in severe respiratory symptoms and heart failure.

Pathophysiology[edit]

PVOD is caused by the progressive blockage of the small pulmonary veins by fibrous tissue. This obstruction impedes the normal flow of blood through the lungs, leading to increased pressure in the pulmonary arteries. Over time, this increased pressure can cause damage to the right ventricle of the heart, as it works harder to pump blood through the narrowed vessels.

Symptoms[edit]

The symptoms of PVOD are similar to those of other forms of pulmonary hypertension and may include:

Diagnosis[edit]

Diagnosing PVOD can be challenging due to its similarity to other types of pulmonary hypertension. Diagnostic methods may include:

Treatment[edit]

There is no cure for PVOD, and treatment primarily focuses on managing symptoms and improving quality of life. Treatment options may include:

Prognosis[edit]

The prognosis for individuals with PVOD is generally poor, with a median survival time of 2-3 years after diagnosis. Early detection and management are crucial for improving outcomes.

See also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.